Discovery of a non-estrogenic irreversible inhibitor of 17β-Hydroxysteroid dehydrogenase type 1 from 3-substituted-16β-(m -carbamoylbenzyl)-estradiol derivatives

Journal of Medicinal Chemistry

Volumn 57, Issue 1, 2014, Pages 204-222

  Maltais, René ^a   Ayan, Diana ^a   Trottier, Alexandre ^a   Barbeau, Xavier ^a   Lagüe, Patrick ^a   Bouchard, Jean Emmanuel ^a   Poirier, Donald ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

(16BETA,17BETA) 16 (3 CARBAMOYLBENZYL) 17 HYDROXY N,N DIMETHYLESTRA 1(10),2,4 TRIENE 3 CARBOXAMIDE; (16BETA,17BETA) 16 (3 CARBAMOYLBENZYL) 17 HYDROXYESTRA 1(10),2,4 TRIENE 3 CARBOXAMIDE; (16BETA,17BETA) 16 (3 CARBAMOYLBENZYL) 17 HYDROXYESTRA 1(10),2,4 TRIENE 3 CARBOXYLIC ACID; (16BETA,17BETA) 16 (3 CARBAMOYLBENZYL) N ETHYL 17 HYDROXY N PROPYLESTRA 1(10),2,4 TRIENE 3 CARBOXAMIDE; (3 [[16BETA,17BETA) 17 HYDROXY 3 (HYDROXYMETHYL)ESTRA 1(10),2,4 TRIEN 16YL]METHYL]BENZAMIDE; 17BETA HYDROXYSTEROID DEHYDROGENASE 1; 3 [[(16BETA,17 BETA) 17 HYDROXY 3 (3 HYDROXYPROPYL)ESTRA 1(10),2,4 TRIEN 16 YL]METHYL]BENZAMIDE; 3 [[(16BETA,17BETA) 17 HYDROXY 3 (2 PHENYLETHYL)ESTRA 1(10),2,4 TRIEN 16YL]METHYL]BENZAMIDE; 3 [[(16BETA,17BETA) 17 HYDROXY 3 (PYRROLIDIN 1 YLCARBONYL)ESTRA 1(10),2,4 TRIENE 16 YL] METHYL]BENZAMIDE; 3 [[(16BETA,17BETA) 17 HYDROXY 3 (PYRROLIDIN 1 YLMETHYL)ESTRA 1(10),2,4 TRIEN 16YL]METHYL]BENZAMIDE; 3 [[(16BETA,17BETA) 3 (2 BROMOETHYL) 17 HYDROXYESTRA 1 (10),2,4 TRIEN 16 YL]METHYL]BENZAMIDE; 3 [[(16BETA,17BETA) 3 (2 CHLOROETHYL) 17 HYDROXYESTRA 1(10),2,4 TRIEN 16 YL]METHYL]BENZAMIDE; 3 [[(16BETA,17BETA) 3 (AMINOMETHYL) 17 HYDROXYESTRA 1(10),2,4 TRIEN 16 YL]METHYL]BENZAMIDE; 3 [[(16BETA,17BETA) 3 (BROMOMETHYL) 17 HYDROXYESTRA 1(10),2,4 TRIEN 16YL]METHYL]BENZAMIDE; 3 [[(16BETA,17BETA) 3 [(DIMETHYLAMINO)METHYL] 1(10),2,4 TRIEN 16YL]METHYL]BENZAMIDE; 3 [[(16BETA,17BETA) 3 [ETHYL(PROPYL)AMINO)METHYL] 17 HYDROXYESTRA 1(10),2,4 TRIEN 16YL]METHYL]BENZAMIDE; 3 [[(16BETA,17BETA) 3 AMINO 17 HYDROXYESTRA 1(10),2,4 TRIEN 16 YL]METHYL]BENZAMIDE; 3 [[(16BETA,17BETA) 3 ETHYL 17 HYDROXYESTRA 1(10),2,4 TRIEN 16 YL]METHYL]BENZAMIDE; 3 [[(16BETA,17BETA) 3 FLUORO 17 HYDROXYESTRA 1(10),2,4 TRIEN 16 YL]METHYL]BENZAMIDE; 3 ETHENYLESTRA 1(10),2,4 TRIEN 17 ONE; [(16BETA,17BETA) 16 (3 CARBAMOYLBENZYL) 17 HYDROXYESTRA 1(10),2,4 TRIEN 3 YL]BORONIC ACID; [3 [3 (BENZYLOXY)PROP 1 EN 1 YL]ESTRA 1(10),2,4 TRIEN 17 ONE]; [3 [[(16BETA,17BETA) 17 HYDROXY 3 (2 IODOETHYL) ESTRA 1(10),2,4 TRIEN 16 YL]METHYL]BENZAMIDE]; [3 [[(16BETA,17BETA) 17 HYDROXY 3 [2 (METHYLAMINO) 2 OXOETHYL]ESTRA 1(10),2,4 TRIEN 16 YL]METHYL]BENZAMIDE]; [3 [[(16BETA,17BETA) 3 (3 BROMOPROPYL) 17 HYDROXYESTRA 1(10),2,4 TRIEN 16 YL]METHYL]BENZAMIDE]; [[(16BETA,17BETA) 16 (3 CARBAMOYLBENZYL) 17 HYDROXYESTRA 1(10),2,4 TRIEN 3 YL]ACETIC ACID]; CYTOCHROME P450 3A4; ESTRADIOL DERIVATIVE; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DEVELOPMENT; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSFORMATION; ENZYME INHIBITION; HYDROGEN BOND; IC 50; MOLECULAR DOCKING; MOLECULAR MODEL; PROTON TRANSPORT; STRUCTURE ACTIVITY RELATION;

17-HYDROXYSTEROID DEHYDROGENASES; CELL PROLIFERATION; DRUG DISCOVERY; ENZYME INHIBITORS; ESTRADIOL; HEK293 CELLS; HUMANS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84892603097     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401639v     Document Type: Article

References (62)

1. U.S. Breast Cancer Statistics; Breastcancer.org: Ardmore, PA, 2013; http://www.breastcancer.org/symptoms/understand-bc/statistics.
2. Cancer Trends Progress Report-2011/2012 Update; National Cancer Institute, NIH, DHHS: Bethesda, MD, August 2012; http://progressreport.cancer. gov.
3. Brueggemeier, R. W.; Hackett, J. C.; Diaz-Cruz, E. S. Aromatase inhibitors in the treatment of breast cancer Endocr. Rev. 2005, 26, 331-345
4. Moeller, G.; Adamski, J. Integrated view on 17beta-hydroxysteroid dehydrogenase Mol. Cell. Endocrinol. 2009, 301, 7-19
5. Penning, T. M. 17beta-Hydroxysteroid dehydrogenase: inhibitors and inhibitor design Endocr.-Relat. Cancer 1996, 3, 41-56
6. von Angerer, E. The estrogen receptor as a target for rational drug design. In Molecular Biology Intelligence Unit; R.G. Landes Company: Austin, TX, 1995.
7. Simard, J.; Vincent, A.; Duchesne, R.; Labrie, F. Full oestrogenic activity of C19-delta 5 adrenal steroids in rat pituitary lactotrophs and somatotrophs Mol. Cell. Endocrinol. 1988, 55, 233-242
8. Nagasaki, S.; Miki, Y.; Akahira, J. I.; Suzuki, T.; Sasano, H. 17β-Hydroxysteroid dehydrogenases in human breast cancer Ann. N. Y. Acad. Sci. 2009, 1155, 25-32
9. Sasano, H.; Frost, A. R.; Saitoh, R.; Harada, N.; Poutanen, M.; Vihko, R.; Bulun, S. E.; Silverberg, S. G.; Nagura, H. Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma J. Clin. Endocrinol. Metab. 1996, 81, 4042-4046
10. Poutanen, M.; Isomaa, V.; Lehto, V. P.; Vihko, R. Immunological analysis of 17beta-hydroxysteroid dehydrogenase in benign and malignant human breast tissue Int. J. Cancer. 1992, 50, 386-390
11. Ariga, N.; Moriya, T.; Suzuki, T.; Kimura, M.; Ohuchi, N.; Satomi, S.; Sasano, H. 17beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast Anticancer Res. 2000, 20, 1101-1108
12. Suzuki, T.; Moriya, T.; Ariga, N.; Kaneko, C.; Kanazawa, M.; Sasano, H. 17beta-Hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters Br. J. Cancer 2000, 82, 518-523
13. Gunnarsson, C.; Hellqvist, E.; Stal, O. 17beta-Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer Br. J. Cancer 2005, 92, 547-552
14. Miyoshi, Y.; Ando, A.; Shiba, E.; Taguchi, T.; Tamaki, Y.; Noguchi, S. Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers Int. J. Cancer 2001, 94, 685-689
15. Chanplakorn, N.; Chanplankorn, P.; Suzuki, T.; Ono, K.; Chan, M. S. M.; Miki, Y.; Saji, S.; Ueno, T.; Toi, M.; Sasano, H. Increased estrogen sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients Breast Cancer Res. Treat. 2010, 120, 639-648
16. Cremoux, P. Hormone therapy and breast cancer Bull. Cancer 2011, 98, 1311-1319
17. Saloniemi, T.; Järvensivu, P.; Koskimies, P.; Jokela, H.; Lamminen, T.; Ghaem-Maghami, S.; Dina, R.; Damdimopoulou, P.; Mäkelä, S.; Perheentupa, A.; Kujari, H.; Brosens, J.; Poutanen, M. Novel hydroxysteroid (17β) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in trangenic mice Am. J. Pathol. 2010, 176, 1443-1451
18. Theobald, A. J. Management of advanced breast cancer with endocrine therapy: the role of the primary healthcare team Int. J. Clin. Pract. 2000, 54, 665-669
19. Dizerega, G. S.; Barber, D. L.; Hodgen, G. D. Endometriosis: role of ovarian steroids in initiation, maintenance, and suppression Fertil. Steril. 1980, 33, 649-653
20. Lanisnik-Rizner, T. Estrogen metabolism and action in endometriosis Mol. Cell. Endocrinol. 2009, 307, 8-18
21. Poirier, D. Inhibitors of 17β-hydroxysteroid dehydrogenase Curr. Med. Chem. 2003, 10, 453-477
22. Day, J. M.; Tutill, H. J.; Purohit, A.; Reed, M. J. Design and validation of specific inhibitors of 17β-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis Endocr.-Relat. Cancer 2008, 15, 665-692
23. Brozic, P.; Lanisnik-Risner, T.; Gobec, S. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 Curr. Med. Chem. 2008, 15, 137-150
24. Poirier, D. Advances in development of inhibitors of 17β- hydroxysteroid dehydrogenases Anticancer Agents Med. Chem. 2009, 9, 642-660
25. Poirier, D. 17β-Hydroxysteroid dehydrogenase inhibitors: a patent review Expert. Opin. Ther. Pat. 2010, 20, 1123-1145
26. Marchais-Oberwinkler, S.; Henn, C.; Moller, G.; Klein, T.; Negri, M.; Oster, A.; Spadaro, A.; Werth, R.; Wetzel, M.; Xu, K.; Frotscher, M.; Hartmann, R. W.; Adamski, J. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic target: protein, structures, functions, and recent progress in inhibitor development J. Steroid Biochem. Mol. Biol. 2011, 125, 66-82
27. Poirier, D. Contribution to the development of inhibitors of 17β-hydroxysteroid dehydrogenase type 1 and 7: key tools for studying and treating estrogen-dependent diseases J. Steroid Biochem. Mol. Biol. 2011, 125, 83-94
28. Lin, S. X.; Poirier, D.; Adamski, J. A challenge for medicinal chemistry by the 17β-hydroxysteroid dehydrogenase superfamily: an integrated biological function and inhibition study Curr. Top. Med. Chem. 2013, 13, 1164-1171
29. + breast cancer cell proliferation induced by estrone Bioorg. Med. Chem. 2008, 16, 1849-1860
30. Laplante, Y.; Rancourt, C.; Poirier, D. Relative involvement of three 17β-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors Mol. Cell. Endocrinol. 2009, 301, 146-153
31. Fang, H.; Tong, W.; Shi, L. M.; Blair, R.; Perkins, R.; Branham, W.; Hass, B. S.; Xie, Q.; Dial, S. L.; Moland, C. L.; Sheehan, D. M. Structure-activity relationships for a large diverse set of natural, synthetic and environmental estrogens Chem. Res. Toxicol. 2001, 14, 280-294
32. Cadot, C.; Laplante, Y.; Kamal, F.; Luu-The, V.; Poirier, D. C6-(N, N -Butyl-methyl- heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17β-hydroxysteroid dehydrogenase: chemical synthesis and biological evaluation Bioorg. Med. Chem. 2007, 15, 714-726
33. Mazumdar, M.; Fournier, D.; Zhu, D. W.; Cadot, C.; Poirier, D.; Lin, S. X. Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy Biochem. J. 2009, 10, 357-366
34. Maltais, R.; Ayan, D.; Poirier, D. Crucial role of 3-bromoethyl side-chain in removing the undesirable estrogenic activity of potent 17β-hydroxysteroid dehydrogenase type 1 inhibitor 16β-(m -carbamoylbenzyl) estradiol ACS Med. Chem. Lett. 2011, 2, 678-681
35. Ahmed, V.; Liu, Y.; Silvestro, C.; Taylor, S. D. Boronic acids as inhibitors of steroid sulfatase Bioorg. Med. Chem. 2006, 14, 8564-8573
36. Radu, I. I.; Poirier, D.; Provencher, L. New efficient pathway for the synthesis of 3-amino-estrone Tetrahedron Lett. 2002, 43, 7616-7619
37. Furuya, T.; Strom, A. E.; Ritter, T. Silver-mediated fluorination of functionalized aryl stannanes J. Am. Chem. Soc. 2009, 131, 1662-1663
38. Morera, E.; Ortar, G. A palladium-catalyzed carbonylative route to primary amides Tetrahedron Lett. 1998, 39, 2835-2838
39. Cacchi, S.; Lupi, A. Palladium-catalyzed hydroxycarbonylation of vinyl and aryl triflates: synthesis of α-β-unsaturated and aromatic carboxylic acids Tetrahedron Lett. 1992, 33, 3939-3942
40. Poirier, D.; Chang, H. J.; Azzi, A.; Boivin, R. P.; Lin, S. X. Estrone and estradiol C-16 derivatives as inhibitors of type 1 17β-hydroxysteroid dehydrogenase Mol. Cell. Endocrinol. 2006, 27, 236-238
41. Allan, G. M.; Lawrence, H. R.; Cornet, J.; Bubert, C.; Fischer, D. S.; Vicker, N.; Smith, A.; Tutill, H. J.; Purohit, A.; Day, J. M.; Mahon, M. F.; Reed, M. J.; Potter, B. V. L. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1 J. Med. Chem. 2006, 49, 1325-1345
42. Skoda-Földes, R.; Kollàr, L.; Marinelli, F.; Arcadi, A. Direct and carbonylative vinylation of steroid triflates in the presence of homogeneous palladium catalysts Steroids 1994, 59, 691-695
43. Gomez, L.; Gellibert, F.; Wagner, A.; Mioskowski, C. (Chloro-phenylthio- methylene)dimethylammonium chloride (CPMA) an efficient reagent for selective chlorination and bromation of primary alcohols Tetrahedron Lett. 2000, 41, 6049-6052
44. Yang, D.; Zhang, C. Ruthenium-catalyzed oxidative cleavage of olefins to aldehydes J. Org. Chem. 2001, 66, 4814-4818
45. Yasu, Y.; Koike, T.; Akita, M. Intermolecular aminotrifluoromethylation of alkenes by visible-light-driven photoredox catalysis Org. Lett. 2013, 15, 2136-2139
46. Rousseau, C.; Christensen, B.; Bols, M. Artificial epoxidase II. Synthesis of cyclodextrin ketoesters and epoxidation of alkenes Eur. J. Org. Chem. 2005, 13, 2734-2739
47. Varghese, J. P.; Sudalai, A.; Iyer, S. Pd-catalysed regiospecific reductive ring opening of epoxides and glycidic esters Synth. Commun. 1995, 25, 2267-2273
48. Ducan, L. J.; Reed, M. J. The role and proposed mechanism by which oestradiol 17β-hydroxysteroid dehydrogenase regulates breast tumour estrogen concentrations J. Steroid Biochem. Mol. Biol. 1995, 55, 565-572
49. Pelletier, J. D.; Poirier, D. Synthesis and evaluation of estradiol derivatives with 16α-(bromoalkylamide), 16α-(bromoalkyl) or 16α-(bromoalkynyl) side chain as inhibitors of 17β-hydroxysteroid dehydrogenase type 1 without estrogenic activity Bioorg. Med. Chem. 1996, 4, 1617-1628
50. Sam, K. M.; Boivin, R. P.; Tremblay, M. R.; Auger, S.; Poirier, D. C16 and C17 derivatives of estradiol as inhibitors of 17β-hydroxysteroid dehydrogenase type 1: chemical synthesis and structure-activity relationships Drug Des. Discovery 1998, 15, 157-180
51. Matthews, J.; Celius, T.; Halgren, R.; Zacharewski, T. Differential estrogen receptor binding of estrogenic substances: a species comparison J. Steroid Biochem. Mol. Biol. 2000, 74, 223-234
52. Kuiper, G. G.; Carlsson, B.; Grandien, K.; Enmark, E.; Haggblad, J.; Nilsson, S.; Gustafsson, J. A. Comparison of the ligand binding specificity and transcript tissues distribution of estrogen receptors α and β Endocrinology 1997, 138, 863-870
53. Ayan, D.; Maltais, R.; Roy, J.; Poirier, D. A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type 1 blocks the estrogen-dependent breast cancer tumor growth induced by estrone Mol. Cancer Ther. 2012, 11, 2096-2104
54. Bydal, P.; Auger, S.; Poirier, D. Inhibition of type 2 17β-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-rings: structure-activity relationship Steroids 2004, 69, 325-342
55. Bellavance, E.; Luu-The, V.; Poirier, D. Potent and selective steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone J. Med. Chem. 2009, 52, 7488-7502
56. Farhane, S.; Fournier, M. A.; Poirier, D. Synthesis and evaluation of amido-deoxyestradiol derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 12 Curr. Enzyme Inhib. 2011, 7, 134-146
57. Marchais-Oberwinkler, S.; Wetzel, M.; Ziegler, E.; Kruchten, P.; Werth, R.; Henn, C.; Hartmann, R. W.; Frotscher, M. New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases J. Med. Chem. 2011, 54, 534-547
58. Poirier, D.; Dionne, P.; Auger, S. A 6β-(thiaheptanamide) derivative of estradiol as inhibitor of 17β-hydroxysteroid dehydrogenase type 1 J. Steroid Biochem. Mol. Biol. 1998, 64, 83-90
59. Yoh, S. D.; Lee, O. S.; Park, J. H.; Kim, S. H.; Lee, Y. D. Solvent effects on the benzylation with substituted imidazoles in acetonitrile and methanol Bull. Korean Chem. Soc. 2000, 21, 653-655
60. Ahn, B. C. Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back Theranostics 2012, 2, 392-402
61. Upadhyay, G.; Singh, R.; Agarwal, G.; Mishra, S. K.; Pal, L.; Pradham, P. K.; Das, B. K.; Godbole, M. M. Functional expression of sodium iodide symporter (NIS) in human breast cancer tissue Breast Cancer Res. Treat. 2003, 77, 157-165
62. Molecular Operating Environment (MOE) 2012.10; Chemical Computing Group Inc., 1010 Sherbrooke St. West, Suite #910, Montréal, QC, Canada H3A 2R7, 2012.